Percutaneous thermoablation of small renal masses (T1a) in surgical candidate patients: oncologic outcomes
- 3 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Radiology
- Vol. 31 (7), 5370-5378
- https://doi.org/10.1007/s00330-020-07496-z
Abstract
Objective To evaluate the local tumour progression–free survival (LTPFS), metastasis-free survival (MFS), cancer-specific survival (CSS) and overall survival (OS) of healthy surgical candidates who underwent percutaneous thermoablation (TA) as a first-line therapy for small renal masses (T1a). Methods The institutional review board approved this bi-institutional retrospective study of 85 consecutive surgical candidates with 97 biopsy-proven malignant renal masses (T1a) treated with percutaneous TA from 2008 to 2016. The LTPFS, MFS, CSS and OS rates were calculated using the Kaplan-Meier method. Descriptive analysis was also performed. Results The median tumour size was 2.3 cm (range, 0.7–3.9 cm). The minimal and mean follow-up periods were 24 and 56 months, respectively. Local recurrence was detected in four patients (4.7%) at 8.5, 13.8, 58.0 and 64.0 months of follow-up and retreated successfully with percutaneous TA. No patient developed metastatic renal cell carcinoma, and none died due to renal oncologic complications. One patient died of heart attack. The 5-year LTPFS, OS, MFS and CSS rates were 93.0%, 98.4%, 100% and 100%, respectively. Only two patients (2.3%) had major complications (Clavien-Dindo grade > II), including ureteropelvic junction stenosis and urinary obstruction due to ureteral blood clots. Conclusions Our study demonstrates that percutaneous TA is a feasible and effective first-line therapy for healthy surgical candidates with small renal masses (T1a). The 5-year LTPFS, OS, CSS and MFS rates were 93.0%, 98.4%, 100% and 100%, respectively, with a major complication rate of only 2.3%. Key Points • Image-guided percutaneous thermoablation of small renal malignancies was effective in 95.3% of the healthy surgical candidates. • Major complications were detected in 2.3% of the patients. • The local tumour progression–free survival rate was 97.6% and 93.0% at 3 and 5 years, respectively.This publication has 35 references indexed in Scilit:
- Renal Mass and Localized Renal Cancer: AUA GuidelineJournal of Urology, 2017
- Renal Ischemia and Function After Partial Nephrectomy: A Collaborative Review of the LiteratureEuropean Urology, 2015
- EAU Guidelines on Renal Cell Carcinoma: 2014 UpdateEuropean Urology, 2015
- Long-term outcomes in healthy adults after radiofrequency ablation of T1a renal tumoursBJU International, 2013
- EAU Guidelines on Renal Cell Carcinoma: The 2010 UpdateEuropean Urology, 2010
- Guideline for Management of the Clinical T1 Renal MassJournal of Urology, 2009
- Nephron-Sparing Surgery for Renal Cell Carcinoma: Detailed Analysis of Complications Over a 15-Year PeriodEuropean Urology, 2006
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationThe New England Journal of Medicine, 2004
- The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremiaKidney International, 2002
- LONG-TERM RESULTS OF NEPHRON SPARING SURGERY FOR LOCALIZED RENAL CELL CARCINOMA: 10-YEAR FOLLOWUPJournal of Urology, 2000